- Home
- / Pharming Group
Pharming Group
Stock Price
$8.7
2024-10-29
Market Capitalization
$590.3 M
2024-10-29
Revenue
$376.1 M
FY, 2025
Pharming Group Summary
Company Summary
- Overview
- Pharming Group is a biopharmaceutical company developing protein replacement therapies and precision medicines for the treatment of rare diseases. Its lead product, RUCONEST, is a recombinant human C1 esterase inhibitor approved for the treatment of acute hereditary angioedema (HAE) attacks.
- Type
- Public
- Status
- Active
- Founded
- 1988
- HQ
- Leiden, NL | view all locations
- Website
- http://www.pharming.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Bruno M. Giannetti, Member of the Board of Management and Chief Medical Officer
Mireille Sanders, Chief Operations Officer
Anne-Marie de Groot, Chief Ethics & Compliance Officer
Operating MetricsView all
Preclinical Phase Products
1
Q3, 2020
Phase I Trials Products
2
Q3, 2020
Phase II Trials Products
1
Q3, 2020
LocationsView all
2 locations detected
Leiden, Zuid-Holland HQ
Netherlands
24 Darwinweg
Leiden, ZH
Netherlands
Vondellaan 47
Pharming Group Financials
Summary Financials
- Revenue (Q1, 2026)
- $72.4M
- Gross profit (Q1, 2026)
- $66.2M
- Net income (Q1, 2026)
- ($5.2M)
- Cash (Q1, 2026)
- $52.4M
- EBIT (Q1, 2026)
- ($5.3M)
- Enterprise value
- $654.1M